Outcome | (n=9) | (n=96) | P-value |
---|---|---|---|
Duration of treatment (months) | Resistant | Nonresistant | |
1-6 | 0 | 15 (16.3) | 0.581 |
7-9 | 3 (3.3) | 32 (34.7) | |
10-12 | 2 (22.2) | 9 (9.2) | |
>12 | 1 (11.1) | 7 (6.1) | |
Loss to follow-up | 3 (33.3) | 33 (33.3) | |
Mean x-bar (excluding loss to follow-up) | 12.00 | 9.46 | |
Standard deviation | 6.033 | 3.711 | |
Side effects | Resistant | Nonresistant | 0.079 |
Drug-induced hepatitis | 1 (11.1) | 12 (12.2) | |
Blurry vision | 1 (11.1) | 1 (1.02) | |
Peripheral neuropathy | 1 (11.1) | 1 (1.02) | |
Joint pain | 0 | 4 (4.1) | |
No side effects | 6 (66.67) | 71 (72.5) | |
Other side effects | 0 | 9 (9.2) | |
Clinical outcome | Resistant | Nonresistant | |
Successful treatment | 5 (55.56) | 51 (53.13) | 0.988 |
Unsuccessful treatment | 1 (11.11) | 12 (12.5) | |
→ Relapse | 0 | 4 | |
→ Death | 1 | 8 | |
Loss to follow-up | 3 (33.33) | 33 (34.38) | |
Length of hospitalization (days) | Resistant | Nonresistant | |
1-25 | 1 | 43 | 0.130 |
26-50 | 2 | 20 | |
>50 | 1 | 11 | |
Unavailability | 5 | 22 | |
Mean x-bar (excluding loss to follow-up) | 38.00 | 36.96 | |
Standard deviation | 20.314 | 53.475 |
Values are presented as numbers and percentages (%).